Multidisciplinary Cancer Investigation
نشریه بین المللی چند تخصصی سرطان
Multidiscip Cancer Investig
Medical Sciences
http://mcijournal.com
1
admin
2476-4922
2538-1911
10.30699/acadpub.mci
en
jalali
1396
7
1
gregorian
2017
10
1
1
Supplement Issue 1: Abstracts of International Tehran Breast Cancer Congress
online
1
fulltext
en
Chitosan-Raloxifene Nanoparticles as a Novel Double Effect Targeting Vehicle for Breast Cancer Cells
Materials Science and Nanomedicine
Original/Research Article
Introduction: Chemotherapeutic drugs such as doxorubicin (DOX) due to their extensive<br>
distribution in both healthy and cancerous cells, lead to severe side effects. One of the<br>
most effective ways to overcome this problem is targeting delivery. Particular characteristics<br>
of chitosan such as cationic nature make its nanoparticles one of the best options for<br>
using as targeting drug carriers. Since nearly 75% of breast cancer cells express the estrogen<br>
receptor (ER), blocking the ER function (using ER antagonists such as Raloxifene) seems<br>
to be effective on reducing the risk of progress in breast cancer. In this study, a novel double<br>
effect nanoparticle based on raloxifene-chitosan conjugate was prepared for adjuvant<br>
therapy and drug targeting to breast cancer cells via ER receptor.<br>
Materials and Methods: CS-RAL NPs containing DOX hydrochloride were prepared by<br>
ionotropic gelation method and characterized by Nanozetasizer and TEM. The effect of<br>
nanoparticles on cell viability was evaluated using XTT assay. Moreover, inhibition tests<br>
were performed by means of Estradiol as the main ligand of estrogen receptor.<br>
Results: CS-RAL NPs containing DOX hydrochloride have sizes between 25-35 nm and<br>
desired zeta potentials. XTT assay on MCF-7 cell line illustrated that nanoparticles containing<br>
doxorubicin could inhibit the cellular growth up to 60%. Results from inhibition<br>
tests showed that in the presence of Estradiol the cell toxicity of prepared nanoparticles<br>
decrease significantly.<br>
Conclusions: This study introduced Raloxifene-Chitosan nanoparticles as a novel targeting<br>
agent for adjuvant therapy of breast cancer.
Chitosan
Raloxifene
Nanoparticles
Targeting Vehicle
Breast Cancer Cells
0
0
http://mcijournal.com/browse.php?a_code=A-10-33-49&slc_lang=en&sid=1
Fatemeh
Yazdi Samadi
1003194753284600755
1003194753284600755
No
Zohreh
Mohammadi
1003194753284600756
1003194753284600756
Yes